166 related articles for article (PubMed ID: 32566037)
1. MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer.
Ye ZQ; Zou CL; Chen HB; Jiang MJ; Mei Z; Gu DN
Dis Markers; 2020; 2020():2782101. PubMed ID: 32566037
[TBL] [Abstract][Full Text] [Related]
2. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
Wang P; Zhuang L; Zhang J; Fan J; Luo J; Chen H; Wang K; Liu L; Chen Z; Meng Z
Mol Oncol; 2013 Jun; 7(3):334-45. PubMed ID: 23177026
[TBL] [Abstract][Full Text] [Related]
3. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer.
Miyamae M; Komatsu S; Ichikawa D; Kawaguchi T; Hirajima S; Okajima W; Ohashi T; Imamura T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Ochiai T; Okamoto K; Taniguchi H; Otsuji E
Br J Cancer; 2015 Nov; 113(10):1467-76. PubMed ID: 26505678
[TBL] [Abstract][Full Text] [Related]
4. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
7. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
8. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression.
Shi W; Zhang C; Ning Z; Hua Y; Li Y; Chen L; Liu L; Chen Z; Meng Z
J Exp Clin Cancer Res; 2019 Feb; 38(1):60. PubMed ID: 30728036
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Hasegawa S; Eguchi H; Nagano H; Konno M; Tomimaru Y; Wada H; Hama N; Kawamoto K; Kobayashi S; Nishida N; Koseki J; Nishimura T; Gotoh N; Ohno S; Yabuta N; Nojima H; Mori M; Doki Y; Ishii H
Br J Cancer; 2014 Oct; 111(8):1572-80. PubMed ID: 25117811
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
[TBL] [Abstract][Full Text] [Related]
13. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
14. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Iwagami Y; Eguchi H; Nagano H; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Tomokuni A; Tomimaru Y; Mori M; Doki Y
Br J Cancer; 2013 Jul; 109(2):502-11. PubMed ID: 23799850
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Ma C; Huang T; Ding YC; Yu W; Wang Q; Meng B; Luo SX
Int J Clin Exp Pathol; 2015; 8(6):6533-9. PubMed ID: 26261532
[TBL] [Abstract][Full Text] [Related]
17. Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.
Panebianco C; Trivieri N; Villani A; Terracciano F; Latiano TP; Potenza A; Perri F; Binda E; Pazienza V
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925948
[TBL] [Abstract][Full Text] [Related]
18. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer.
LaConti JJ; Shivapurkar N; Preet A; Deslattes Mays A; Peran I; Kim SE; Marshall JL; Riegel AT; Wellstein A
PLoS One; 2011; 6(6):e20687. PubMed ID: 21738581
[TBL] [Abstract][Full Text] [Related]
19. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
20. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
